http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Ophthalmic+News/Article/list/2695 Major Ophthalmic Industry News delivered twice a month. 2009-11-21T16:41:59Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Inspire-initiates-phase-II-trials-with-azithr/ArticleStandard/Article/detail/596780?contextCategoryId=2695&ref=25 Inspire Pharmaceuticals Inc. announced it has initiated two phase II clinical trials with azithromycin ophthalmic solution 1% (AzaSite) to pursue a potential indication for the treatment of blepharitis. The drug currently is approved by the FDA for the treatment of bacterial conjunctivitis. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596780null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Clinical+News/ARVO-Novagali-Pharma-IND-cleared-for-phase-III-stu/ArticleStandard/Article/detail/596779?contextCategoryId=2695&ref=25 Novagali Pharma announced that the company's investigational new drug application to conduct a phase III clinical trial of Nova21027 (Catioprost), a cationic emulsion of latanoprost for the treatment of glaucoma, has been granted by the FDA. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596779null HTML http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/Ophthalmic+News/ARVO-Second-Sight-doubles-patient-enrollment-for-r/ArticleStandard/Article/detail/596778?contextCategoryId=2695&ref=25 Second Sight Medical Products Inc. announced that the FDA has granted approval for up to 20 people who are blind or who have severely impaired vision due to retinitis pigmentosa to participate in a feasibility study for its retinal implant (Argus II Retinal Implant) in the United States. Ten RP volunteers are participating in the U.S. study and an additional 12 RP volunteers are participating in similar studies throughout Europe and Mexico. 2009-05-06T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/192009/596778null HTML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Wilmer-Eye-Institute-breaks-ground-on-new-upgraded/ArticleStandard/Article/detail/443738?contextCategoryId=2695&ref=25 The Wilmer Eye Institute of Johns Hopkins University School of Med-icine opened a $100 million, privately funded, 207,000-square-foot facility that will build on the current research and clinical space for its 130 full-time faculty (90 clinician scientists; 40 PhD researchers). 2007-07-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/302007/443738null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Trials-to-test-efficacy-of-ocular-implants/ArticleStandard/Article/detail/439337?contextCategoryId=2695&ref=25 Lincoln, RI?Biotechnology firm Neurotech Pharmaceuticals Inc. has begun two phase II/III clinical trials with NT-501, the company's lead Encapsulated Cell Technology (ECT) product for the treatment of visual loss associated with retinitis pigmentosa. 2007-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/272007/439337null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/AMO-phaco-system-offers-dual-pump-fluidics/ArticleStandard/Article/detail/439333?contextCategoryId=2695&ref=25 San Diego?Advanced Medical Optics (AMO) Inc. has introduced a new phacoemulsification system featuring dual-pump fluidics (WhiteStar Signature with Fusion). 2007-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/272007/439333null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Cyclosporine-A-tested-for-dry-eye/ArticleStandard/Article/detail/439338?contextCategoryId=2695&ref=25 Tampa, FL?Two companies are researching cyclosporine A as a potential treatment for dry eye syndrome. 2007-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/272007/439338null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Photochromic-IOL-to-be-available-in-Europe/ArticleStandard/Article/detail/439334?contextCategoryId=2695&ref=25 Irvine, CA?Medennium Inc. expects that its photochromic IOL (Aurium) will be available in all European countries by September now that it has obtained CE mark clearance to market the lens. It is the first and only photochromic IOL, according to the company. 2007-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/272007/439334null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Trials-begin-on-drop-to-heal-ocular-wounds/ArticleStandard/Article/detail/439339?contextCategoryId=2695&ref=25 Bethesda, MD?The FDA will allow Regene-Rx Biopharmaceuticals Inc. to begin a phase II trial of its Thymosin beta 4 (TB4) for the treatment of diabetic patients undergoing vitrectomy surgery. 2007-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/272007/439339null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Spreading-agent-introduced-to-market/ArticleStandard/Article/detail/439335?contextCategoryId=2695&ref=25 San Diego?Baxter Healthcare Corp. has launched its hyaluronidase human injection (Hylenex recombinant) for use in enhancing the absorption and dispersion of injected ophthalmic anesthetics. 2007-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/272007/439335null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/AMO-recalls-lens-solution/ArticleStandard/Article/detail/439328?contextCategoryId=2695&ref=25 In response to reports received from the Centers for Disease Control and Prevention (CDC) regarding eye infections from Acanthamoeba, Advanced Medical Optics (AMO) has voluntarily recalled its Complete MoisturePlus contact lens solutions. No evidence suggests that the voluntary recall is related to a product contamination issue, according to AMO. The company is working with the CDC, FDA, and others to ensure that consumers are aware of the need for proper contact lens disinfection and proper lens handling. 2007-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/272007/439328null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Therapy-improves-visual-field-defect/ArticleStandard/Article/detail/439336?contextCategoryId=2695&ref=25 Boston--More than 70% of stroke and traumatic brain injury (TBI) survivors with homonymous visual-field defects demonstrated a visual field improvement of more than 3% following a six-module course of vision restoration therapy, according to a study released by NovaVision. 2007-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/272007/439336null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/The-price-of-vision/ArticleStandard/Article/detail/439331?contextCategoryId=2695&ref=25 Chicago?The aggregate cost related to adult vision conditions in the United States has climbed to an estimated $51.4 billion, according to a pioneering report from Prevent Blindness America (PBA). 2007-06-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/272007/439331null XML http://www.modernmedicine.com/modernmedicine/Industry+News/ASCRS-launches-ectasia-registry/ArticleStandard/Article/detail/435733?contextCategoryId=2695&ref=25 The American Society of Cataract and Refractive Surgery (ASCRS) has launched the ASCRS International Ectasia Registry as part of a two-phase project to define ectasia more precisely, determine its frequency, and identify risk factors. 2007-06-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435733null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Bausch-amp-Lomb-to-merge-with-private-equity-firm/ArticleStandard/Article/detail/435730?contextCategoryId=2695&ref=25 After more than 150 years in business (69 of them as a public company), Bausch & Lomb has accepted an offer to merge with Warburg Pincus, a private equity firm. 2007-06-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435730null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/FDA-OKs-azithromycin-1-ophthalmic-solution/ArticleStandard/Article/detail/435735?contextCategoryId=2695&ref=25 InSite Vision Inc. expects its azithromycin 1% ophthalmic solution (Aza- Site) to be launched commercially in the United States in the second half of this year now that the FDA has approved the company's new drug application. 2007-06-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435735null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Bepotastine-promising-against-ocular-itching/ArticleStandard/Article/detail/435734?contextCategoryId=2695&ref=25 Preliminary phase II/III results of a clinical trial of bepotastine for the treatment of allergic conjunctivitis show statistically significant results against some symptoms, according to ISTA Pharmaceuticals Inc. 2007-06-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435734null XML http://www.modernmedicine.com/modernmedicine/Plastics/Horizontal-tightening-of-upper-eyelid-helps-with-f/ArticleStandard/Article/detail/434925?contextCategoryId=2695&ref=25 Horizontal eyelid tightening alone results in secondary improvement in the ptosis associated with floppy eyelid syndrome, according to the results of a case series in 24 eyelids of 18 patients. 2007-05-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/242007/434925null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Iridex-settles-with-Synergetics/ArticleStandard/Article/detail/435767?contextCategoryId=2695&ref=25 S 2007-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435767null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Accommodating-IOL-leads-revenue-surge/ArticleStandard/Article/detail/435765?contextCategoryId=2695&ref=25 Aliso Viejo, CA—First-quarter 2007 revenues for eyeonics inc., the developer of the crystalens accommodating IOL, have increased 36% over the same period last year, the company said. 2007-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435765null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/State-policies-reviewed-at-first-Vision-Summit/ArticleStandard/Article/detail/435766?contextCategoryId=2695&ref=25 Vision health advocates convened here to review data and the effectiveness of various state policy models to provide children's vision care in what is touted as the first "Vision Summit." 2007-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435766null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/475-million-grant-to-fund-stem-cell-work/ArticleStandard/Article/detail/435764?contextCategoryId=2695&ref=25 The Lincy Foundation has given the first installment of a 4-year, $4.75 million grant to the Oregon Retinal Degeneration Center at Oregon Health & Science (OHSU) Casey Eye Institute. 2007-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435764null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Protective-eye-gear-essential-for-modern-soldier/ArticleStandard/Article/detail/435761?contextCategoryId=2695&ref=25 Preventing ocular injuries during war by using protective devices may reduce the incidence of these injuries, which currently hold the number four slot for highest incidence after amputation, traumatic brain injury, and post-traumatic stress disorder. 2007-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435761null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Phase-II-trial-to-study-DME/ArticleStandard/Article/detail/435763?contextCategoryId=2695&ref=25 The Juvenile Diabetes Research Foundation (JDRF) is enrolling patients in a study to test the long-term safety and effectiveness of intraocular injections of ranibizumab (Lucentis, Genentech) in patients with diabetic macular edema (DME) 2007-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435763null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Generic-drug-sale-blocked-until-2009/ArticleStandard/Article/detail/435762?contextCategoryId=2695&ref=25 A federal appellate court has blocked the largest Canadian-owned pharmaceutical company from manufacturing and selling a generic version of Allergan's ketorolac tromethamine ophthalmic solution 0.5% (Acular). 2007-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435762null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Robert-Osher-MD-treasures-his-Charles-Kelman-Award/ArticleStandard/Article/detail/435760?contextCategoryId=2695&ref=25 Robert H. Osher, MD, has received numerous accolades over his lifetime as an innovative surgeon, video producer, athletic coach, professor, and medical director of a large practice. But, he said, the Charles Kelman Award he received recently from the Hellenic Society of Intraocular Implant & Refractive Surgery is among his most treasured. 2007-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435760null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/CDC-examines-apparent-Acanthamoeba-keratitis-outbr/ArticleStandard/Article/detail/435759?contextCategoryId=2695&ref=25 Ophthalmologists and epidemiologists around the country are growing concerned about an apparent increase in the number of Acanthamoeba keratitis cases they are seeing. 2007-05-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435759null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Carl-Zeiss-Vision-announces-Howard-as-new-presiden/ArticleStandard/Article/detail/435345?contextCategoryId=2695&ref=25 Frederick Howard has been named the new president and general manager, Americas, for Carl Zeiss Vision. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435345null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Ophthonix-picks-Osbaldeston-as-chief-executive-off/ArticleStandard/Article/detail/435443?contextCategoryId=2695&ref=25 Ophthonix has named Stephen J. Osbaldeston as its chief executive officer. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435443null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Topigen-Pharmaceuticals-Novagali-Pharma-to-collabo/ArticleStandard/Article/detail/435342?contextCategoryId=2695&ref=25 Topigen Pharmaceuticals and Novagali Pharma will collaborate on products designed to improve the bioadhesion and efficacy of RNA-targeting therapeutics delivered to the nasal membrane and ocular surface. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435342null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Newly-formed-Opko-Corp-plans-to-study-wet-AMD-ther/ArticleStandard/Article/detail/435341?contextCategoryId=2695&ref=25 Newly formed Opko Corp. plans a phase III trial of bevasiranib (formerly Cand5) as maintenance therapy for wet AMD in combination with ranibizumab (Lucentis, Genentech). 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435341null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Anti-VEGF-peptide-near-phase-I-clinical-trials/ArticleStandard/Article/detail/435343?contextCategoryId=2695&ref=25 Potentia Pharmaceuticals said it would initiate phase I clinical trials to evaluate its drug POT-4, for the treatment of age-related macular degeneration (AMD). 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435343null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Dr-Singh-appointed-editor-of-British-Journal-of-Op/ArticleStandard/Article/detail/435347?contextCategoryId=2695&ref=25 Arun D. Singh, MD, has been named editor of the British Journal of Ophthalmology (USA). 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435347null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Iridex-Synergetics-square-off-to-settle-patent-dis/ArticleStandard/Article/detail/435442?contextCategoryId=2695&ref=25 Iridex Corp. and Synergetics USA Inc. are headed to trial to settle a patent dispute. Iridex claims that Synergetics relied on its patented technology to create a connector for handheld probes it sold between 1999 and mid-2006. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435442null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Dr-Osher-to-sign-copies-of-his-books-for-children-/ArticleStandard/Article/detail/435344?contextCategoryId=2695&ref=25 Robert H. Osher, MD, carves time out of his professional, academic, and personal responsibilities to write books for children. He will sign copies of seven of his titles during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435344null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Ostrov-joins-NuLens-board-of-directors/ArticleStandard/Article/detail/435346?contextCategoryId=2695&ref=25 NuLens has named Gerald M. Ostrov to its board of directors. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435346null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/VEGF-drug-improves-vision-in-patients-with-wet-AMD/ArticleStandard/Article/detail/435340?contextCategoryId=2695&ref=25 Based on a planned, interim analysis of a phase II randomized study, Regeneron Pharmaceuticals and Bayer HealthCare said patients with wet age-related macular degeneration (AMD) who received just one dose of their vascular endothelial growth factor (VEGF) drug (Trap-Eye) maintained or improved vision at 12 weeks. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435340null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/NicOx-Pfizer-announce-phase-II-trial-of-latanopros/ArticleStandard/Article/detail/435339?contextCategoryId=2695&ref=25 NicOx and Pfizer will initiate a phase II, dose-finding study of its PF-03187207 compound for the treatment of patients with glaucoma and ocular hypertension. The 28-day trial is designed to compare the safety and efficacy of the drug with that of latanoprost (Xalatan, Pfizer Ophthalmics). 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435339null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Ziemer-Group-to-take-on-sales-marketing-of-keratom/ArticleStandard/Article/detail/435338?contextCategoryId=2695&ref=25 Ziemer Group will take on the worldwide sales, marketing, and support activities for an automated microkeratome (Amadeus II) and all related accessories and consumables. The product line is engineered and manufactured by a Ziemer Group company, SIS Surgical Instrument Systems Ltd. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435338null XML http://www.modernmedicine.com/modernmedicine/Industry+News/Ophthalmology-Times-wins-two-2007-Neal-Awards-for-/ArticleStandard/Article/detail/435332?contextCategoryId=2695&ref=25 Ophthalmology Times magazine earned two awards in the 53rd annual Jesse H. Neal National Business Journalism Awards competition recognizing editorial excellence. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435332null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Bausch-amp-Lomb-earns-NTIOL-status-for-two-lens-pr/ArticleStandard/Article/detail/435337?contextCategoryId=2695&ref=25 Bausch & Lomb has earned NTIOL status for its SofPort Advanced Optics and SofPort Advanced Optics with Violet Shield lenses. 2007-04-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/252007/435337null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Six-researchers-win-100000-grants/ArticleStandard/Article/detail/418294?contextCategoryId=2695&ref=25 Fort Worth, TX—The Alcon Research Institute (ARI) has given six ocular researchers $100,000 each to further their research endeavors. 2007-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/418294null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Extra-review-delays-lens-approval/ArticleStandard/Article/detail/418292?contextCategoryId=2695&ref=25 Monrovia, CA—STAAR Surgical Co. says the application for its toric phakic implantable IOL (Visian TICL) will be submitted to the Ophthalmic Devices Panel of the FDA's Center for Devices and Radiological Health for evaluation, delaying the approval it had hoped would come later this year. 2007-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/418292null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Dr-Campbell-joins-Sophrona-advisory-board/ArticleStandard/Article/detail/418289?contextCategoryId=2695&ref=25 Minneapolis—Robert C. Campbell, MD, has joined the advisory board of Sophrona Solutions. 2007-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/418289null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Texas-centers-ready-to-help-restore-sight/ArticleStandard/Article/detail/418296?contextCategoryId=2695&ref=25 Boca Raton, FL—Nova Vision Inc. has installed its device (Vision Restoration Therapy [VRT]) in two centers in Texas, where therapists can help restore sight to people who have been left partially blind by a stroke or brain injury. 2007-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/418296null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Range-expands-for-accommodating-IOL/ArticleStandard/Article/detail/418295?contextCategoryId=2695&ref=25 Aliso Viejo, CA—eyeonics Inc. has expanded the range of its accommodating lens (crystalens Five-O) to benefit patients with larger eyes and more precise diopter needs. 2007-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/418295null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Dr-Khurana-receives-AMA-Foundation-award/ArticleStandard/Article/detail/418290?contextCategoryId=2695&ref=25 Washington, DC—Rahul N. Khurana, MD, from Santa Monica, CA, has been named a recipient of the American Medical Association (AMA) Foundation's 2007 Leadership Award. This award provides medical students, residents/fellows, young physicians, and international medical graduate physicians from around the country with special training to develop their skills as future leaders in organized medicine. 2007-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/418290null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/University-of-Iowa-launches-Project-3000/ArticleStandard/Article/detail/418291?contextCategoryId=2695&ref=25 Iowa City, IA—The University of Iowa is launching Project 3000 in an effort to identify all 3,000 U.S. men, women, and children who have Leber's congenital amaurosis (LCA). 2007-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/418291null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/BampL-recalls-second-contact-lens-solution/ArticleStandard/Article/detail/418288?contextCategoryId=2695&ref=25 Rochester, NY—Bausch & Lomb is voluntarily recalling about 1.5 million bottles of its contact lens solution (ReNu MultiPlus) after it discovered elevated levels of trace iron had caused some of the solution to discolor and lose effectiveness. 2007-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/418288null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Inspire-agrees-to-sell-InSite-anti-infective/ArticleStandard/Article/detail/418293?contextCategoryId=2695&ref=25 Alameda, CA—Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.'s topical anti-infective for treating bacterial conjunctivitis (AzaSite). 2007-04-01T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/418293null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Ranibizumab-approved-for-use-in-Europe/ArticleStandard/Article/detail/417521?contextCategoryId=2695&ref=25 Basel, Switzerland—The European Union has approved ranibizumab (Lucentis, Genentech) as a new treatment for patients with wet age-related macular degeneration (AMD). 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417521null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Vision-care-bill-touted-on-Capitol-Hill/ArticleStandard/Article/detail/417613?contextCategoryId=2695&ref=25 Washington, DC—Vision advocates met with more than 60 participants of a recent congressional briefing and press conference to raise awareness about a vision-care bill for children. 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417613null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Latanoprost-derivatives-show-help-for-glaucoma/ArticleStandard/Article/detail/417612?contextCategoryId=2695&ref=25 Sophia Antipolis, France—Nitric oxide-donating derivatives of latanoprost (Xalatan) are showing an improved ability to lower IOP for the treatment of glaucoma, according to preclinical results of research conducted by NicOx SA and Pfizer Inc. 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417612null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Once-daily-drug-as-safe-as-original-formula/ArticleStandard/Article/detail/417611?contextCategoryId=2695&ref=25 Lrvine, CA—ISTA Pharmaceuticals Inc. said its bromfenac sodium ophthalmic solution (Xibrom) once-daily formulation produced highly statistically significant results in its phase III clinical trials. 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417611null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/OXiGENE-appoints-Kollins-to-business-development-p/ArticleStandard/Article/detail/417608?contextCategoryId=2695&ref=25 Waltham, MA—OXiGENE Inc., a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced that John A. Kollins has joined the company as senior vice president and chief business officer. In the latter role, Kollins will be responsible for all business development activities as well as commercial strategy for the company. 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417608null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Ophthalmology-Times-is-a-finalist-for-Pulitzer-Pri/ArticleStandard/Article/detail/417607?contextCategoryId=2695&ref=25 Cleveland—Ophthalmology Times magazine has been named a finalist in the 53rd annual Jesse H. Neal National Business Awards competition recognizing editorial excellence. The awards, which have been called the Pulitzer Prizes of the business press, are sponsored by American Business Media, an association of business information providers. 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417607null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Study-patients-with-poor-vision-incur-greater-medi/ArticleStandard/Article/detail/417606?contextCategoryId=2695&ref=25 Baltimore—The impact of poor vision costs Medicare more than $2 billion each year for non-eye-care-related concerns, prompting a call by some to put further emphasis on vision health for all Americans. 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417606null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Wet-AMD-treatment-approved-in-Europe/ArticleStandard/Article/detail/417614?contextCategoryId=2695&ref=25 Toronto—Novadaq Technologies said the European Union has approved the OPTTX System, a minimally invasive treatment for wet age-related macular degeneration. 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417614null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Dr-Whitman-elected-president-of-ACES/ArticleStandard/Article/detail/417609?contextCategoryId=2695&ref=25 Dallas—The American College of Eye Surgeons (ACES) has named Jeffrey Whitman, MD, president of the national organization for a 2-year term. Dr. Whitman is medical director and chief surgeon of Dallas-based Key-Whitman Eye Center and has been practicing ophthalmic surgery for more than 20 years. 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417609null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Spanish-Portuguese-translations-offered-at-Wilmer-/ArticleStandard/Article/detail/417610?contextCategoryId=2695&ref=25 Baltimore—Wilmer Eye Institute's Current Concepts in Ophthalmology meeting here in April promises a uniquely international flair because it will be presented in English with simultaneous translations into Spanish and Portuguese. 2007-03-15T04:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/152007/417610null XML http://www.modernmedicine.com/modernmedicine/Ophthalmology/Dr-Tasman-to-step-down-at-Wills-Eye-Jefferson/ArticleStandard/Article/detail/408522?contextCategoryId=2695&ref=25 Philadelphia—William S. Tasman, MD, is preparing to step down from his positions as ophthalmologist-in-chief at the Wills Eye Institute and chairman of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University here. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/092007/408522null HTML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Dr-Peli-receives-Lighthouses-2006-Pisart-Award/ArticleStandard/Article/detail/410627?contextCategoryId=2695&ref=25 New York—Lighthouse International has bestowed its 2006 Pisart Award on Eliezer (Eli) Peli, MSc, OD, professor of ophthalmology, Harvard Medical School, and the Moakley Scholar in Aging Eye Research, Schepens Eye Research Institute, Boston. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410627null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Dr-Coca-Prados-serves-as-visiting-professor/ArticleStandard/Article/detail/410626?contextCategoryId=2695&ref=25 New Haven, CT—Glaucoma researcher Miguel Coca-Prados, PhD, recently has completed a professorship at Pfizer's Groton Laboratories as the 2006 Yale-Pfizer Global Discovery Visiting Professor. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410626null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Duke-spin-off-firm-wins-FDA-marketing-approval/ArticleStandard/Article/detail/410630?contextCategoryId=2695&ref=25 Research Triangle Park, NC—The FDA has approved marketing to begin for a new, non-invasive eye scanner developed by a company spun off from Duke University's biomedical engineering department. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410630null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Pfizer-MediVas-team-for-ophthalmic-drug-delivery/ArticleStandard/Article/detail/410634?contextCategoryId=2695&ref=25 New York—Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410634null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Deformable-mirror-yields-clearer-view-of-retina/ArticleStandard/Article/detail/410635?contextCategoryId=2695&ref=25 Watertown, MA—Boston Micromachines Corp., which provides MEMS-based deformable mirror products for adaptive optics systems, has created an enhanced deformable mirror for ultra-high-resolution retinal imaging. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410635null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Alcon-revamps-Web-site-access-to-resources/ArticleStandard/Article/detail/410632?contextCategoryId=2695&ref=25 Fort Worth, TX—Alcon Laboratories has redesigned its Web site to deliver online eye health information more easily to physicians, patients, and their families. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410632null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Genentech-letter-warns-of-stroke-risk-with-ranibiz/ArticleStandard/Article/detail/410624?contextCategoryId=2695&ref=25 South San Francisco—Genentech Inc. is advising ophthalmologists that it is seeing a slightly higher incidence of stroke among patients using the 0.5-mg dose of its ranibizumab injection (Lucentis) to treat wet age-related macular degeneration (AMD). 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410624null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Phase-III-trials-begin-for-steroid-compound/ArticleStandard/Article/detail/410636?contextCategoryId=2695&ref=25 Tampa—Sirion Therapeutics Inc. has begun enrolling patients in two phase III clinical trials to evaluate difluprednate (ST-601), a steroid compound to treat inflammation after ocular surgery. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410636null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/DME-drug-to-begin-phase-I-trial-this-year/ArticleStandard/Article/detail/410633?contextCategoryId=2695&ref=25 Vancouver—iCo Therapeutics Inc. said the FDA has accepted an investigational new drug application for iCo-007 to treat diabetic macular edema (DME). 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410633null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Dr-Sutphin-joins-University-of-Kansas-medical-facu/ArticleStandard/Article/detail/410625?contextCategoryId=2695&ref=25 Kansas City, KS—John E. Sutphin Jr., MD, an expert in cornea and transplant and refractive surgery, has joined the faculty of the University of Kansas School of Medicine as professor and chairman of the ophthalmology department. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410625null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Vail-meeting-an-annual-tradition-for-Wilmer-instit/ArticleStandard/Article/detail/410628?contextCategoryId=2695&ref=25 Vail, CO—The Wilmer Ophthalmological Institute at Johns Hopkins University School of Medicine will host its 24th annual Current Concepts in Ophthalmology meeting here March 11 to 16. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410628null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Medicare-patients-now-have-access-to-toric-IOLs/ArticleStandard/Article/detail/410629?contextCategoryId=2695&ref=25 Washington, DC—A Jan. 22 ruling by the Centers for Medicare and Medicaid Services (CMS) gives Medicare beneficiaries undergoing cataract surgery the option to have a toric IOL implanted. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410629null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Corneal-implant-made-for-severe-keratoconus/ArticleStandard/Article/detail/410637?contextCategoryId=2695&ref=25 Des Plaines, IL—Addition Technology Inc. has completed the first worldwide shipment of its corneal implant (Intacs SK) for patients with severe keratoconus. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410637null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Akorn-seeks-approval-for-ocular-anesthetic/ArticleStandard/Article/detail/410631?contextCategoryId=2695&ref=25 Buffalo Grove, IL—Akorn Inc.'s ocular anesthetic (AK-1015 [now named Akten]) has met its endpoints in a phase III trial. The four-arm, randomized, placebo-controlled trial tested three different doses. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410631null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Developing-global-research-collaborations-a-priori/ArticleStandard/Article/detail/410638?contextCategoryId=2695&ref=25 Las Vegas—India is now considered a model in the development of international research collaborations in the field of ophthalmology. Its success is based on the ability of individuals to cooperate through mutual respect, transparency, humor, and friendship, said R.D. Thulasiraj, MBA, here at the American Academy of Ophthalmology annual meeting held in conjunction with the Association for Research in Vision and Ophthalmology. 2007-03-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/112007/410638null XML http://www.modernmedicine.com/modernmedicine/Cornea/BampL-shows-interest-in-corneal-device/ArticleStandard/Article/detail/405953?contextCategoryId=2695&ref=25 Rochester, NY—Bausch & Lomb has made an equity investment in—and secured an exclusive option to purchase—AcuFocus Inc., a developer of corneal inlay technology for treating presbyopia. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405953null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Antihistamine-acquired-from-Alimera-Sciences/ArticleStandard/Article/detail/405954?contextCategoryId=2695&ref=25 Rochester, NY—Bausch & Lomb has purchased Alimera Sciences' over-the-counter allergy franchise, including ketotifen fumarate ophthalmic solution 0.025% (Alaway), which was recently approved by the FDA. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405954null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Genaera-drops-plan-for-wet-AMD-drug/ArticleStandard/Article/detail/405957?contextCategoryId=2695&ref=25 Plymouth Meeting, PA—Genaera Corp. has decided to terminate its clinical development program for squalamine lactate (Evizon) for the treatment of wet age-related macular degeneration (AMD) after a comprehensive review of its portfolio and market conditions. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405957null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Bill-would-fund-vision-care-for-kids/ArticleStandard/Article/detail/405950?contextCategoryId=2695&ref=25 Washington, DC—A bipartisan group of federal legislators has introduced a bill in the House and Senate designed to provide follow-up care for children with identified potential vision problems. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405950null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Gel-could-treat-viral-eye-infection/ArticleStandard/Article/detail/405961?contextCategoryId=2695&ref=25 Tampa—Sirion Therapeutics Inc. has made an exclusive licensing agreement with Laboratoires Thea of France for U.S. rights to develop and market a topical ophthalmic gel containing ganciclovir for treating certain viral and superficial eye infections. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405961null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Farzad-Yaghouti-MD-voted-Best-LASIK-Surgeon-2006/ArticleStandard/Article/detail/405949?contextCategoryId=2695&ref=25 San Diego—Farzad Yaghouti, MD, chief refractive surgeon at Global Laser Vision San Diego, won the 2006 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405949null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Orphan-status-given-to-two-drugs/ArticleStandard/Article/detail/405960?contextCategoryId=2695&ref=25 Jersey City, NJ—The FDA has granted orphan drug designation to two investigational therapeutics of Lux Biosciences, a privately held biotechnical company specializing in treatments for ophthalmic diseases. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405960null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/IRIDEX-gets-patents-for-Laserscope-aesthetics/ArticleStandard/Article/detail/405955?contextCategoryId=2695&ref=25 Mountain View, CA—IRIDEX Corp. has completed its acquisition of San Jose, CA-based Laserscope's aesthetics business. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405955null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Register-early-to-save-review-fees/ArticleStandard/Article/detail/405952?contextCategoryId=2695&ref=25 San Francisco—Ophthalmologists preparing for the 2007 American Board of Ophthalmology Demonstration of Ophthalmic Cognitive Knowledge examination can save money by registering for a review course before April 19. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405952null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Sodium-hyaluronate-compound-studied/ArticleStandard/Article/detail/405959?contextCategoryId=2695&ref=25 Chapel Hill, NC—Lantibio Inc. and TRB Chemedica have begun a phase III clinical trial with VISMED, a patented formulation containing sodium hyaluronate, to treat dry eye syndrome. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405959null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Dr-Kameen-and-family-aid-Baltimore-program/ArticleStandard/Article/detail/405946?contextCategoryId=2695&ref=25 Baltimore—Anthony J. Kameen, MD, and his family received a proclamation from outgoing Maryland Gov. Robert L. Ehrlich as a tribute to their involvement with the Helping Up Mission of Baltimore. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405946null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Viewpoint-Be-an-advocate-for-surgery-by-surgeons-u/ArticleStandard/Article/detail/405945?contextCategoryId=2695&ref=25 Las Vegas—Ophthalmologists have made great headway in the past year to ensure that surgery remains with surgeons, specifically in Oklahoma, where optometrists' efforts have been thwarted. Ophthalmologists, however, must continue this vigilance. One way to do so is by contributing to the American Academy of Ophthalmology (AAO) Surgical Scope Fund, according to Randolph Johnston, MD, the AAO's senior secretary for advocacy. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405945null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Allergan-donates-1M-for-research-fellows/ArticleStandard/Article/detail/405962?contextCategoryId=2695&ref=25 Irvine, CA—Allergan will donate $1 million over 2 years to academic medical institutions to support fellows researching glaucoma and corneal and retinal diseases. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405962null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Optos-names-new-chief-executive-officer/ArticleStandard/Article/detail/405947?contextCategoryId=2695&ref=25 Dunfermline, U.K.—Optos plc has appointed Thomas W. Butts as chief executive officer and a member of the board of directors. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405947null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Visiogen-continues-study-of-dual-optic-IOL/ArticleStandard/Article/detail/405958?contextCategoryId=2695&ref=25 Irvine, CA—Visiogen Inc. says it has received FDA approval to expand its phase III U.S. clinical trial for its dual-optic accommodating IOL (Synchrony). 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405958null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Isis-appoints-Dr-Jonas-as-executive-vice-president/ArticleStandard/Article/detail/405948?contextCategoryId=2695&ref=25 Carlsbad, CA—Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405948null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/FDA-seeks-answers-before-approving-drug/ArticleStandard/Article/detail/405951?contextCategoryId=2695&ref=25 Irvine, CA—Allergan Inc. is continuing to evaluate a clinical study of its brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% (Combigan) in an effort to address FDA questions prior to final marketing approval. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405951null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Eye-firms-win-as-best-places-to-work/ArticleStandard/Article/detail/405956?contextCategoryId=2695&ref=25 New York—Genentech Inc. and Alcon Laboratories Inc. have once again made the Fortune magazine top 100 list of best companies for which to work. 2007-02-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/082007/405956null XML http://www.modernmedicine.com/modernmedicine/News/AMO-acquires-WaveFront-Sciences/ArticleStandard/Article/detail/401151?contextCategoryId=2695&ref=25 Santa Ana, CA—In a move designed to boost its quest for the "custom all-laser LASIK," Advanced Medical Optics (AMO) has acquired WaveFront Sciences, Albuquerque, NM, for about $20 million. 2007-02-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052007/401151null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/BampL-to-undergo-management-changes-in-Americas-re/ArticleStandard/Article/detail/401153?contextCategoryId=2695&ref=25 Rochester, NY—Bausch & Lomb (B&L) will undergo a realignment of management responsibilities for its Americas region. The changes follow the announcement by Paul G. Howes, currently senior vice president and president-Americas Region, that he intends to resign from the company. Howes will remain with the company to effect an orderly transition to the new management structure. 2007-02-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052007/401153null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Geneticist-retinal-expert-joins-Jules-Stein-Eye-In/ArticleStandard/Article/detail/401152?contextCategoryId=2695&ref=25 Los Angeles—The Jules Stein Eye Institute (JSEI) and the Department of Ophthalmology of the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), have appointed Michael Gorin, MD, the Harold and Pauline Price Chair in Ophthalmology and professor of ophthalmology in the retina and vision science divisions. 2007-02-01T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/052007/401152null XML http://www.modernmedicine.com/modernmedicine/News/Conjunctival-PAM-uncommon-but-important-disease/ArticleStandard/Article/detail/398673?contextCategoryId=2695&ref=25 Las Vegas—Primary acquired melanosis (PAM) of the conjunctiva is an uncommon but important disease. Although some studies have suggested that it occurs in as much as one-third of the population, most cases do not need treatment. The disease is potentially malignant, however, and arguments can be made for early treatment if risk factors are present, said Jerry A. Shields, MD, in his delivery of the Lorenz E. Zimmerman Lecture here at a combined meeting of the American Academy of Ophthalmology and the American Association of Ocular Pathologists. 2007-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/032007/398673null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Clinical-trial-under-way-for-topical-AMD-therapy/ArticleStandard/Article/detail/398679?contextCategoryId=2695&ref=25 San Diego—TargeGen has begun a phase I trial of a topical drug to treat age-related macular degeneration (AMD). 2007-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/032007/398679null XML http://www.modernmedicine.com/modernmedicine/Ophthalmic+News/Novel-AMD-drug-being-tested-on-15-patients/ArticleStandard/Article/detail/398676?contextCategoryId=2695&ref=25 Redwood City, CA—The first of 15 patients has received CGC-11047, a novel poly-amine analog that targets choroidal neovascularization associated with age-related macular degeneration. 2007-01-15T05:00:00Z http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/data/articlestandard/ophthalmologytimes/032007/398676null XML